{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:07:41Z","timestamp":1778659661964,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40256-018-00318-0","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T01:48:40Z","timestamp":1549936120000},"page":"325-334","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and Safety of Ticagrelor Compared with Clopidogrel in Patients with End-Stage Renal Disease with Acute Myocardial Infarction"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1123-2440","authenticated-orcid":false,"given":"Chien-Ho","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Hsien","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Jui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-kai","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Jung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-I","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,12]]},"reference":[{"issue":"10","key":"318_CR1","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1082\u2013115.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"318_CR2","doi-asserted-by":"publisher","first-page":"888","DOI":"10.4070\/kcj.2017.0072","volume":"47","author":"C Kim","year":"2017","unstructured":"Kim C, Shin DH, Ahn CM, Kim JS, Kim BK, Ko YG, et al. The use pattern and clinical impact of new antiplatelet agents including Prasugrel and Ticagrelor on 30-day outcomes after acute myocardial infarction in Korea: Korean health insurance review and assessment data. Korean Circ J. 2017;47(6):888\u201397.","journal-title":"Korean Circ J"},{"issue":"11","key":"318_CR3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357.","journal-title":"N Engl J Med"},{"issue":"3","key":"318_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267\u2013315.","journal-title":"Eur Heart J"},{"issue":"8","key":"318_CR5","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1093\/ndt\/gft103","volume":"28","author":"T Gremmel","year":"2013","unstructured":"Gremmel T, Muller M, Steiner S, Seidinger D, Koppensteiner R, Kopp CW, et al. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol Dial Transpl. 2013;28(8):2116\u201322.","journal-title":"Nephrol Dial Transpl"},{"issue":"9","key":"318_CR6","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.amjcard.2009.06.049","volume":"104","author":"SH Park","year":"2009","unstructured":"Park SH, Kim W, Park CS, Kang WY, Hwang SH, Kim W. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol. 2009;104(9):1292\u20135.","journal-title":"Am J Cardiol"},{"issue":"3","key":"318_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/ehjcvp\/pvv052","volume":"2","author":"LZ Guo","year":"2016","unstructured":"Guo LZ, Kim MH, Shim CH, Choi SY, Serebruany VL. Impact of renal impairment on platelet reactivity and clinical outcomes during chronic dual antiplatelet therapy following coronary stenting. Eur Heart J Cardiovasc Pharmacother. 2016;2(3):145\u201351.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"6","key":"318_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1053\/j.ajkd.2011.12.027","volume":"59","author":"C Muller","year":"2012","unstructured":"Muller C, Caillard S, Jesel L, El Ghannudi S, Ohlmann P, Sauleau E, et al. Association of estimated GFR with platelet inhibition in patients treated with clopidogrel. Am J Kidney Dis. 2012;59(6):777\u201385.","journal-title":"Am J Kidney Dis"},{"issue":"21","key":"318_CR9","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1161\/CIRCULATIONAHA.111.084996","volume":"125","author":"D Capodanno","year":"2012","unstructured":"Capodanno D, Angiolillo DJ. Antithrombotic therapy in patients with chronic kidney disease. Circulation. 2012;125(21):2649\u201361.","journal-title":"Circulation."},{"issue":"11","key":"318_CR10","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1161\/CIRCULATIONAHA.110.974683","volume":"122","author":"G Montalescot","year":"2010","unstructured":"Montalescot G, Silvain J. Ticagrelor in the renal dysfunction subgroup: subjugated or substantiated? Circulation. 2010;122(11):1049\u201352.","journal-title":"Circulation."},{"issue":"11","key":"318_CR11","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","volume":"122","author":"S James","year":"2010","unstructured":"James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2010;122(11):1056\u201367.","journal-title":"Circulation."},{"issue":"4","key":"318_CR12","doi-asserted-by":"publisher","first-page":"e001116","DOI":"10.1161\/JAHA.114.001116","volume":"3","author":"TM Blicher","year":"2014","unstructured":"Blicher TM, Hommel K, Kristensen SL, Torp-Pedersen C, Madsen M, Kamper AL, et al. Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease\u2014a Danish nation-wide cohort study. J Am Heart Assoc. 2014;3(4):e001116.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"318_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1525-139X.2006.00179.x","volume":"19","author":"D Kaw","year":"2006","unstructured":"Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial. 2006;19(4):317\u201322.","journal-title":"Semin Dial."},{"issue":"4","key":"318_CR14","doi-asserted-by":"publisher","first-page":"e28099","DOI":"10.5812\/numonthly.28099","volume":"7","author":"F Summaria","year":"2015","unstructured":"Summaria F, Giannico MB, Talarico GP, Patrizi R. Antiplatelet therapy in hemodialysis patients undergoing percutaneous coronary interventions. Nephro-Urol Mon. 2015;7(4):e28099.","journal-title":"Nephro-Urol Mon."},{"issue":"3","key":"318_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.109.865352","volume":"121","author":"CS Fox","year":"2010","unstructured":"Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010;121(3):357\u201365.","journal-title":"Circulation."},{"issue":"6","key":"318_CR16","doi-asserted-by":"crossref","first-page":"e002069","DOI":"10.1161\/JAHA.115.002069","volume":"4","author":"T Gupta","year":"2015","unstructured":"Gupta T, Paul N, Kolte D, Harikrishnan P, Khera S, Aronow WS, et al. Association of chronic renal insufficiency with in-hospital outcomes after percutaneous coronary intervention. J Am Heart Assoc. 2015;4(6):e002069.","journal-title":"J Am Heart Assoc."},{"issue":"18","key":"318_CR17","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.jacc.2011.06.056","volume":"58","author":"TT Tsai","year":"2011","unstructured":"Tsai TT, Messenger JC, Brennan JM, Patel UD, Dai D, Piana RN, et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry\u2014CMS claims database. J Am Coll Cardiol. 2011;58(18):1859\u201369.","journal-title":"J Am Coll Cardiol."},{"issue":"7","key":"318_CR18","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/S0735-1097(02)01745-X","volume":"39","author":"PJ Best","year":"2002","unstructured":"Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002;39(7):1113\u20139.","journal-title":"J Am Coll Cardiol."},{"issue":"6","key":"318_CR19","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1053\/j.ajkd.2014.11.023","volume":"65","author":"KH Jeong","year":"2015","unstructured":"Jeong KH, Cho JH, Woo JS, Kim JB, Kim WS, Lee TW, et al. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. Am J Kidney Dis. 2015;65(6):916\u201324.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"318_CR20","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1111\/j.1538-7836.2011.04531.x","volume":"9","author":"D Alexopoulos","year":"2011","unstructured":"Alexopoulos D, Panagiotou A, Xanthopoulou I, Komninakis D, Kassimis G, Davlouros P, et al. Antiplatelet effects of prasugrel vs double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. J Thromb Haemost. 2011;9(12):2379\u201385.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"318_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1053\/j.ajkd.2012.05.001","volume":"60","author":"D Alexopoulos","year":"2012","unstructured":"Alexopoulos D, Xanthopoulou I, Plakomyti TE, Goudas P, Koutroulia E, Goumenos D. Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis. Am J Kidney Dis. 2012;60(2):332\u20133.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"318_CR22","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","volume":"11","author":"GN Levine","year":"2014","unstructured":"Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol. 2014;11(10):597\u2013606.","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"318_CR23","doi-asserted-by":"publisher","first-page":"899.e1","DOI":"10.1016\/j.ahj.2015.03.015","volume":"169","author":"HJ Kang","year":"2015","unstructured":"Kang HJ, Clare RM, Gao R, Held C, Himmelmann A, James SK, et al. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the platelet inhibition and patient outcomes (PLATO) trial. Am Heart J. 2015;169(6):899.e1\u2013905.e1.","journal-title":"Am Heart J"},{"issue":"215","key":"318_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ijcard.2016.04.044","volume":"15","author":"KH Park","year":"2016","unstructured":"Park KH, Jeong MH, Ahn Y, Ahn TH, Seung KB, Oh DJ, et al. Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health. Int J Cardiol. 2016;15(215):193\u2013200.","journal-title":"Int J Cardiol"},{"key":"318_CR25","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.carrev.2018.01.009","volume":"19","author":"N Misumida","year":"2018","unstructured":"Misumida N, Aoi S, Kim SM, Ziada KM, Abdel-Latif A. Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: systematic review and meta-analysis. Cardiovasc Revasc Med Incl Mol Interv. 2018;19:689\u201394.","journal-title":"Cardiovasc Revasc Med Incl Mol Interv"},{"issue":"23","key":"318_CR26","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1093\/eurheartj\/ehr422","volume":"32","author":"RC Becker","year":"2011","unstructured":"Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011;32(23):2933\u201344.","journal-title":"Eur Heart J"},{"issue":"8","key":"318_CR27","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/pds.4002","volume":"25","author":"C Collette","year":"2016","unstructured":"Collette C, Clerc-Urmes I, Laborde-Casterot H, Frimat L, Ayav C, Peters N, et al. Antiplatelet and oral anticoagulant therapies in chronic hemodialysis patients: prescribing practices and bleeding risk. Pharmacoepidemiol Drug Safety. 2016;25(8):935\u201343.","journal-title":"Pharmacoepidemiol Drug Safety"},{"issue":"3","key":"318_CR28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/CCM.0b013e318206ccc3","volume":"39","author":"TH Tsai","year":"2011","unstructured":"Tsai TH, Chua S, Hussein H, Leu S, Wu CJ, Hang CL, et al. Outcomes of patients with Killip class III acute myocardial infarction after primary percutaneous coronary intervention. Crit Care Med. 2011;39(3):436\u201342.","journal-title":"Crit Care Med."},{"issue":"2","key":"318_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0735-1097(03)00572-2","volume":"42","author":"AK Berger","year":"2003","unstructured":"Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42(2):201\u20138.","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"318_CR30","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1253\/circj.CJ-14-0633","volume":"79","author":"S Grall","year":"2015","unstructured":"Grall S, Biere L, Le Nezet M, Bouvier JM, Lucas-Chauvelon P, Richard C, et al. Relationship between beta-blocker and angiotensin-converting enzyme inhibitor dose and clinical outcome following acute myocardial infarction. Circ J. 2015;79(3):632\u201340.","journal-title":"Circ J"},{"issue":"1","key":"318_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000336154","volume":"121","author":"MS Marcolino","year":"2012","unstructured":"Marcolino MS, Simsek C, de Boer SP, van Domburg RT, van Geuns RJ, de Jaegere P, et al. Short- and long-term major adverse cardiac events in patients undergoing percutaneous coronary intervention with stenting for acute myocardial infarction complicated by cardiogenic shock. Cardiology. 2012;121(1):47\u201355.","journal-title":"Cardiology."},{"issue":"7","key":"318_CR32","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jacc.2015.11.048","volume":"67","author":"RU Shah","year":"2016","unstructured":"Shah RU, de Lemos JA, Wang TY, Chen AY, Thomas L, Sutton NR, et al. Post-hospital outcomes of patients with acute myocardial infarction with cardiogenic shock: findings from the NCDR. J Am Coll Cardiol. 2016;67(7):739\u201347.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"318_CR33","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.ijcard.2010.12.081","volume":"157","author":"A Shalev","year":"2012","unstructured":"Shalev A, Zahger D, Novack V, Etzion O, Shimony A, Gilutz H, et al. Incidence, predictors and outcome of upper gastrointestinal bleeding in patients with acute coronary syndromes. Int J Cardiol. 2012;157(3):386\u201390.","journal-title":"Int J Cardiol"},{"issue":"8","key":"318_CR34","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","volume":"114","author":"JW Eikelboom","year":"2006","unstructured":"Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8):774\u201382.","journal-title":"Circulation."},{"issue":"4","key":"318_CR35","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00380-014-0504-9","volume":"30","author":"TH Lin","year":"2015","unstructured":"Lin TH, Lai WT, Kuo CT, Hwang JJ, Chiang FT, Chang SC, et al. Additive effect of in-hospital TIMI bleeding and chronic kidney disease on 1-year cardiovascular events in patients with acute coronary syndrome: data from Taiwan Acute Coronary Syndrome Full Spectrum Registry. Heart Vessel. 2015;30(4):441\u201350.","journal-title":"Heart Vessel."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-018-00318-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-018-00318-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-018-00318-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T19:04:13Z","timestamp":1662923053000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-018-00318-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,12]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1007\/s40256-018-00318-0","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,12]]},"assertion":[{"value":"12 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"C-HL, T-HT, C-JL, S-KH, W-JC, and C-IC have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}